Open AccessEffect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome
Author(s) -
Michelle L. O’Donoghue,
Eugene Braunwald,
Harvey D. White,
Dylan P. Steen,
Mary Ann Lukas,
Elizabeth Tarka,
Philippe Gabríel Steg,
Judith S. Hochman,
Christoph Bode,
Aldo P. Maggioni,
KyungAh Im,
Jennifer B. Shan,
Richard Y. Davies,
Sabina A. Murphy,
Sharon Crugnale,
Stephen D. Wiviott,
Marc P. Bonaca,
David F. Watson,
W. Douglas Weaver,
Patrick W. Serruys,
Christopher P. Can
Publication year - 2014
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2014.11061
Subject(s) - medicine , acute coronary syndrome , myocardial infarction , hazard ratio , timi , cardiology , clinical endpoint , placebo , chest pain , stroke (engine) , randomized controlled trial , percutaneous coronary intervention , confidence interval , pathology , mechanical engineering , alternative medicine , engineering
Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related to inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA2 enzyme.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom